Inquis Medical today announced findings from the AVENTUS trial evaluating the safety and efficacy of its Aventus thrombectomy system.
Aventus features proprietary tissue-sensing technology. It provides operators with real-time information on the tissue composition in contact with the device. The system offers enhanced precision and control during procedures, Inquis said in a news release. Last year, the system won FDA 510(k) clearance along with Inquis’ blood return system for peripheral indications. The company brought in a $40 million Series B funding round at the end of 2024 as well.
Menlo Park, California-based Inquis completed enrollment in this FDA investigational device exemption (IDE) study in January. The study included 130 patients with acute intermediate-risk pulmonary embolism (PE) across 22 U.S. sites. It evaluated patients aged 18 to 80 years.
Dr. Jun Li, co-director of the Vascular Center and Pulmonary Embolism Response Team at University Hospitals Harrington Heart & Vascular Institute, served as principal investigator. Li presented findings at the 2025 Society of Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions in Washington, D.C.
AVENTUS successfully met its primary endpoints, demonstrating safety and efficacy in treating acute intermediate-risk PE patients.
Results showed significant improvement in right ventricular function and reduction in clot burden. Patients experienced minimal blood loss and short ICU and total hospital stays. Investigators reported no device-related major adverse events, too.
The study saw meaningful improvements in patient-reported quality of life, according to a news release. It also had a significant increase in six-minute walk test distance through 30 days.
“The Aventus system appears to offer a new option in the treatment of PE based on the trial’s safety and efficacy data,” said Dr. Saher Sabri, national co-principal investigator of the AVENTUS trial, lead author on the JSCAI publication, professor and chief of interventional radiology at Georgetown University School of Medicine. “The trial included 49 unique users across 22 sites, and looks to deliver consistent outcomes including minimal blood loss and no device-related major adverse events. Improvement in functional outcomes at 30 days was also demonstrated across the study cohort.”
